Topic: management changes
Novartis rejigged its exec team to further big ambitions for digital tech, tighten up compliance and replace its head of operations.
Gilead's executive v.p. of worldwide commercial operations is unexpectedly retiring, at a time when the company is facing challenges across its infectious-disease and oncology portfolios.
Monday, Axovant said COO Marion McCourt would be exit “to pursue another opportunity.” Turns out, that opportunity's at Regeneron.
Celgene Chairman Bob Hugin, an influential figure in biotech, will bid goodbye to that company next week. Where might he go next?
GlaxoSmithKline CEO Emma Walmsley has replaced 40% of the company’s top management as she aims to reposition the struggling pharma giant.
Novartis' soon-to-be-ex CEO Joe Jimenez has nailed at least one new job: board member at P&G, courtesy of a proxy fight at the consumer giant.
Bayer's consumer health ambitions have been frustrated by declining U.S. sales, and now it's shaking up management to get the unit back on track.
Pfizer now has a chief operating officer and, potentially, a successor to CEO Ian Read: Albert Bourla, who now heads its Innovative Health unit.
What comes after a successful M&A hunt at Gilead Sciences? A promotion for the executive who sewed up its $11.9 billion deal for Kite Pharma.
Lilly CEO David Ricks has overhauled his team twice since he took over in January, and this time he's focusing on manufacturing, tech and R&D.